publication . Article . 2015

LE MEDICAMENT DU MOIS. Vedolizumab (Entyvio(R)), nouveau traitement des maladies inflammatoires intestinales.

Van Kemseke, Catherine; Louis, Edouard; REENAERS, Catherine;
Open Access French
  • Published: 01 Jan 2015
  • Country: Belgium
Anti-TNF agents are highly effective in treating inflammatory bowel diseases, but loss of response and side-effects leading to drug interruption are often reported. New molecules are needed to treat these patients. Vedolizumab is a fully humanized anti-body inhibiting the migration of circulating lymphocytes to the gut by binding the integrin alpha4beta7. In ulcerative colitis, clinical response, remission and mucosal healing were observed at 6 weeks in 47%, 17% and 40% of the patients, respectively. The maintenance study demonstrated 42% and 52% of clinical remission and response at week 52. In Crohn's disease, clinical response and remission were respectively ...
free text keywords: Antibodies, Monoclonal, Humanized/pharmacology, Clinical Trials as Topic, Gastrointestinal Agents/pharmacology, Humans, Inflammatory Bowel Diseases/drug therapy, : Gastroenterology & hepatology [Human health sciences], : Gastroentérologie & hépatologie [Sciences de la santé humaine]
Related Organizations
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue